Cellectis (NASDAQ:CLLS) Now Covered by Analysts at StockNews.com

Equities researchers at StockNews.com assumed coverage on shares of Cellectis (NASDAQ:CLLS) in a research report issued on Tuesday. The brokerage set a “sell” rating on the biotechnology company’s stock.

Separately, Barclays lowered their price objective on shares of Cellectis from $7.00 to $5.00 and set an “overweight” rating for the company in a research report on Tuesday, November 5th.

Cellectis Stock Up 29.1 %

Cellectis stock opened at $1.82 on Tuesday. Cellectis has a twelve month low of $1.41 and a twelve month high of $3.38. The stock has a market cap of $101.16 million, a P/E ratio of -1.40 and a beta of 3.09. The company’s 50-day moving average price is $1.84 and its two-hundred day moving average price is $2.02. The company has a quick ratio of 1.78, a current ratio of 1.78 and a debt-to-equity ratio of 0.48.

Cellectis (NASDAQ:CLLS) last released its quarterly earnings results on Monday, November 4th. The biotechnology company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.03). The firm had revenue of $18.05 million for the quarter, compared to analyst estimates of $5.00 million. Cellectis had a negative return on equity of 74.55% and a negative net margin of 234.39%. During the same period in the previous year, the business posted ($0.31) earnings per share. As a group, analysts expect that Cellectis will post -0.46 EPS for the current year.

Institutional Trading of Cellectis

Several hedge funds have recently made changes to their positions in the company. Long Focus Capital Management LLC raised its holdings in shares of Cellectis by 2.9% in the 2nd quarter. Long Focus Capital Management LLC now owns 4,617,293 shares of the biotechnology company’s stock valued at $8,634,000 after acquiring an additional 130,000 shares in the last quarter. Principal Financial Group Inc. lifted its position in Cellectis by 2.9% during the second quarter. Principal Financial Group Inc. now owns 437,000 shares of the biotechnology company’s stock valued at $817,000 after purchasing an additional 12,467 shares during the last quarter. First Affirmative Financial Network purchased a new position in Cellectis in the 3rd quarter worth approximately $45,000. Finally, XTX Topco Ltd bought a new position in shares of Cellectis in the 2nd quarter worth $29,000. 63.90% of the stock is currently owned by institutional investors.

About Cellectis

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.